TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04280510

Intervention type: GENETIC
Intervention: Blood sample collection; gastrointestinal biopsy
Description: Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

Intervention type: GENETIC
Intervention: Blood sample collection; gastrointestinal biopsy
Description: Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Study: NCT02551939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Description: Autologous Fat Grafting
Study: NCT02643914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Compatible Nicotine Delivery Device
Study: NCT01626469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril
Description: 25mg Captopril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril
Description: 25mg Captopril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00651690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection on Day 0
Study: NCT04002232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP-NaF varnish
Description: calcium phosphate containing fluoride releasing varnish to prevent caries

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPP-ACP-NaF varnish
Description: calcium phosphate containing fluoride releasing varnish to prevent caries
Study: NCT00640016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT-354 10 mg/kg
Description: CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
Study: NCT01287065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF(100mcg)/Vilanterol(25mcg) AM
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF(100mcg)/Vilanterol(25mcg) PM
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo AM
Description: Inhalation powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AM
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo PM
Description: Inhalation powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PM
Description: Inhalation powder
Study: NCT02885090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
Study: NCT05049486

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: Patients will undergone a pelvic CT scan.
Study: NCT01214187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled carbon monoxide
Description: The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: Room air oxygen concentrations will be administered as placebo
Study: NCT01270087

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: 40 mg IV every 14 days
Study: NCT02587429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Study: NCT04040400

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy (IORT)
Description: intraoperative radiotherapy (IORT) during brain tumor resection to establish a maximum tolerated dose (MTD) through a dose-escalation trial using intraoperative radiotherapy (IORT)
Study: NCT02691260

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incentives for dietary self-monitoring
Description: Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incentives for interim weight loss
Description: Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentives for both
Description: Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
Study: NCT03798223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLT
Description: A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
Study: NCT03498846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified EA and AMLK
Description: Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LA and AMLK
Description: A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
Study: NCT03334409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study: NCT01964807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette, NIDA test type with 16.6 mg nicotine
Description: Smoke a single cigarette for up to 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette, NIDA test type with <0.45 mg nicotine
Description: Smoke a single low-nicotine cigarette for up to 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette with 18 mg/ml nicotine
Description: Use electronic cigarette with 18 mg/ml nicotine for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette with no nicotine
Description: Use electronic cigarette with no nicotine for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moist snuff
Description: Use moist snuff for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Smoking
Description: Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Smoking
Description: Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand cigarette smoke (SHS)
Description: 180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned, filtered air
Description: Exposure to conditioned, filtered air for 180 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Moist Snuff
Description: Chew gum for 30 minutes
Study: NCT00975715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRI476
Description: TRI476 oral suspension doses, based on body weight twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TRI476
Description: Placebo oral suspension, taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benzodiazepines
Description: Benzodiazepines could be used as needed as rescue medication during the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Description: Benzodiazepines could be used as needed as rescue medication during the duration of the study.
Study: NCT04209465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-189
Description: Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-189
Description: Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.
Study: NCT03937726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled peanut
Description: Desensitisation using boiled peanut for induction and initial updosing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Defatted roasted peanut flour
Description: Desensitisation using defatted peanut flour for induction and initial updosing
Study: NCT03035903

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Not holding, then holding the MedGem®
Description: Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Not holding, then holding the MedGem®
Description: Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holding, then not holding the MedGem®
Description: Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holding, then not holding the MedGem®
Description: Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
Study: NCT01839500

Intervention type: DRUG
Intervention: Trastuzumab
Description: Trastuzumab administered in accordance with routine care practice.
Study: NCT03252054

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for memory disorders, attention disorders, and malnutrition
Description: Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
Study: NCT00261846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing.
Study: NCT00555542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
Study: NCT01601847

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
Study: NCT01660126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects \<50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is \<0.4 mU/L dose will be reduced by 25 µg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00325039

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retropubic mid-urethral sling (TVT)
Description: This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transobturator mid-urethral sling (TVT-O and the Monarc)
Description: This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
Study: NCT02639468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke Volume estimation using electrical impedance tomography
Study: NCT00954174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00350662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: 75 mg/kg body weight daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Description: 75 mg/kg body weight daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desferrioxamine
Description: In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desferrioxamine
Description: In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
Study: NCT00670189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923 (XL139)
Description: Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
Study: NCT02249767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne once daily in evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne once daily in evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne once daily in evening
Study: NCT04054609

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FAZA PET/MRI scan
Description: PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
Study: NCT03327116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: oral, 15 mg per week, 24 weeks
Study: NCT02311998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study: NCT02736136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: joint observation and video feedback
Study: NCT04580797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 IR
Description: Immediate release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 IR
Description: Immediate release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 IR
Description: Immediate release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 IR
Description: Immediate release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 IR
Description: Immediate release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 IR
Description: Immediate release formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR1
Description: Modified release formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR1
Description: Modified release formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR1
Description: Modified release formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR1
Description: Modified release formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR1
Description: Modified release formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR1
Description: Modified release formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR2
Description: Modified release formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR2
Description: Modified release formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR2
Description: Modified release formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR2
Description: Modified release formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR2
Description: Modified release formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR2
Description: Modified release formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR3
Description: Modified release formulation 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR3
Description: Modified release formulation 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 MR3
Description: Modified release formulation 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT03241212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
Study: NCT02092350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Grazoprevir
Description: Placebo tablet matched to grazoprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Elbasvir
Description: Placebo tablet matched to elbasvir
Study: NCT04379050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI).
Study: NCT00809211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study